HHS Seeks Public Input to Improve Access to Deceased Donor Islet Cell Treatments - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

HHS Invites Public Feedback on Enhancing Access to Islet Cell Treatments from Deceased Donors

  • By

  • Assistant Secretary for Public Affairs (ASPA)

  • September 23, 2026

Share

Clinical Scorecard: HHS Invites Public Feedback on Enhancing Access to Islet Cell Treatments from Deceased Donors

At a Glance

CategoryDetail
ConditionType 1 Diabetes
Key MechanismsDeceased donor pancreatic islet cells may restore insulin production in recipients.
Target PopulationIndividuals with type 1 diabetes requiring insulin therapy.
Care SettingRegulatory framework for transplantation of deceased donor islet cells.

Key Highlights

  • HHS is evaluating FDA regulations that may limit access to islet cell therapies.
  • Islet transplantation may decrease or eliminate the need for insulin in recipients.
  • Feedback is sought on whether unmodified islet cells should be classified as organs.
  • Current FDA oversight ensures safety and effectiveness of islet cell products.
  • Public comments are invited until November 8, 2026.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients with type 1 diabetes potentially benefiting from islet cell transplantation.

          Islet cells from deceased donors may provide a life-changing therapy for insulin production.

          Clinical Best Practices

          • Maintain stringent safety and quality requirements in islet cell transplantation.
          • Consider patient access barriers arising from current FDA regulations.

          Related Resources & Content

          Original Source(s)

          Related Content